Literature DB >> 20924092

Haemogenic endothelium in infantile haemangioma.

Tinte Itinteang1, Swee T Tan, Helen Brasch, Darren J Day.   

Abstract

BACKGROUND: Proliferating infantile haemangioma (IH) is a tumour of the microvasculature composed predominantly of immature endothelial cells. The origin of IH is unclear, but it has been shown to express markers of both endothelial and haematopoietic lineages, and a role for endothelial progenitor cells in the aetiology of IH has been suggested. Haemangioblasts are precursors of both endothelial and haematopoietic cells, and their characterisation has identified the expression of cell surface and intracellular proteins that collectively can be used for assigning a haemangioblast phenotype.
METHODS: The authors used immunohistochemical staining to characterise the expression of primitive haematopoietic-associated proteins in proliferating IHs. RESULTS AND DISCUSSION: The authors show that the cells forming the capillary endothelium express markers associated with primitive haematopoietic cells. Additionally, many of these cells express the transcription factors brachyury and GATA-2, indicating a primitive mesodermal origin. They hypothesise that the immature capillaries in IH are derived from primitive mesodermal cells with haemangioblastic differentiation capabilities. The expression of primitive mesodermal, endothelial and haematopoietic markers by the cells forming the endothelium suggests that the immature capillaries that predominate in proliferating IH are a haemogenic endothelium phenotype, derived from haemangioblasts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924092     DOI: 10.1136/jcp.2010.081257

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Infantile hemangiomas: A review.

Authors:  Alison B Callahan; Michael K Yoon
Journal:  Saudi J Ophthalmol       Date:  2012-05-23

Review 2.  Insights Into Vascular Anomalies, Cancer, and Fibroproliferative Conditions: The Role of Stem Cells and the Renin-Angiotensin System.

Authors:  Ethan J Kilmister; Swee T Tan
Journal:  Front Surg       Date:  2022-04-27

3.  Expression of Cathepsins B, D, and G in Infantile Hemangioma.

Authors:  Tinte Itinteang; Daria A Chudakova; Jonathan C Dunne; Paul F Davis; Swee T Tan
Journal:  Front Surg       Date:  2015-06-17

Review 4.  Biology of infantile hemangioma.

Authors:  Tinte Itinteang; Aaron H J Withers; Paul F Davis; Swee T Tan
Journal:  Front Surg       Date:  2014-09-25

5.  Proliferating Infantile Hemangioma Tissues and Primary Cell Lines Express Markers Associated with Endothelial-to-Mesenchymal Transition.

Authors:  Tinte Itinteang; Cherise E S Tan; Bede van Schaijik; Reginald W Marsh; Paul F Davis; Swee T Tan
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-02-11

Review 6.  Cell Populations Expressing Stemness-Associated Markers in Vascular Anomalies.

Authors:  Ethan J Kilmister; Lauren Hansen; Paul F Davis; Sean R R Hall; Swee T Tan
Journal:  Front Surg       Date:  2021-02-09

7.  Angiotensin-converting Enzyme Inhibitors: Can it be a Potential Treatment of Infantile Hemangioma.

Authors:  Archika Gupta; Shiv Narain Kureel; Anand Pandey; Gurmeet Singh; Akhilesh Kumar; Gaurav Shandilya; Rahul Kumar Rai; Survesh Kumar Gupta
Journal:  J Indian Assoc Pediatr Surg       Date:  2021-07-12

Review 8.  The modern primitives: applying new technological approaches to explore the biology of the earliest red blood cells.

Authors:  Stuart T Fraser
Journal:  ISRN Hematol       Date:  2013-10-03

9.  Phosphorylated Forms of STAT1, STAT3 and STAT5 Are Expressed in Proliferating but Not Involuted Infantile Hemangioma.

Authors:  Lucy Sulzberger; Elysia M S Tan; Paul F Davis; Helen D Brasch; Swee T Tan; Tinte Itinteang
Journal:  Front Surg       Date:  2018-04-19

Review 10.  Regulating the Polarization of Macrophages: A Promising Approach to Vascular Dermatosis.

Authors:  Huiling Peng; Dehai Xian; Jiexiong Liu; Shihong Pan; Ran Tang; Jianqiao Zhong
Journal:  J Immunol Res       Date:  2020-07-28       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.